Imaging assessment of tumor densities and sizes following pazopanib treatment for central nervous system solitary fibrous tumors with multiple extracranial metastases: A case series.

ABSTRACT: Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare but aggressive, often metastasizing to extracranial regions, with no established treatments apart from surgery. Pazopanib, a multikinase angiogenesis inhibitor, is used to treat extracranial SFTs; however, its efficacy for treating CNS SFTs remains unclear. To address this issue, the efficacy of pazopanib was investigated, focusing on tumor density and size in CNS SFTs with extracranial metastases after initiation, interruption or resumption of pazopanib treatment. The present study retrospectively reviewed 3 consecutive cases of CNS SFTs showing extracranial metastases that were referred to Kochi Health Sciences Center (Kochi, Japan) between January 2018 and April 2024 and were treated with pazopanib. All measurable lesi

SUBMITTER: Tsuno T 

PROVIDER: S-EPMC11566106 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature